文献速递免疫规划卫生政策与健康促进

中国12岁女性青少年不同人乳头瘤病毒疫苗接种策略的卫生经济学评价

[Health economics evaluation of vaccination strategies for different human papillomavirus vaccines for 12-year-old female adolescents in China].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2025-01-01

本研究建立决策树-马尔科夫模型,模拟2023年中国12岁女性青少年队列,分析接种2剂二价、四价、九价HPV疫苗与不接种的成本效用。结果显示三种策略均具成本效用,二价HPV疫苗ICUR为-28470.44元/QALY,最具经济性。

要点

  • 12岁女性接种2剂HPV-2、HPV-4、HPV-9与不接种相比均具成本效用。
  • HPV-2的ICUR为-28470.44元/QALY,可净节省成本,最具经济性。
  • 概率敏感性分析显示HPV-2、HPV-4、HPV-9具成本效用的概率分别为99.51%、89.03%、67.81%。

核心结论

  • 在HPV-2采用试点省份招采价格、多价疫苗采用50%自费接种价格的情况下,12岁女性青少年接种HPV-2、HPV-4、HPV-9均具有成本效用,HPV-2是最具经济性的策略。

研究设计与样本

  • 建立决策树-马尔科夫模型,以生殖器疣和宫颈癌为目标疾病,模拟2023年12岁女性青少年队列,分析不接种、接种2剂HPV-2、2剂HPV-4、2剂HPV-9策略的成本效用。

主要发现

  • 与不接种相比,HPV-2可避免55.2%的宫颈癌发生,HPV-4可避免77.11%的生殖器疣和54.99%的宫颈癌发生,HPV-9可避免78.68%的生殖器疣和73.46%的宫颈癌发生。
  • HPV-2、HPV-4、HPV-9策略的ICUR分别为-28470.44元/QALY、29328.26元/QALY、48106.85元/QALY。
  • 单因素敏感性分析显示影响较大的因素为贴现率、疫苗价格、低级别癌前病变直接医疗成本。
  • 概率敏感性分析显示,与2023年全国人均GDP比较,HPV-2、HPV-4、HPV-9与不接种相比具有成本效用的概率分别为99.51%、89.03%、67.81%。
  • 单剂HPV-4、HPV-9疫苗价格分别低于当前自费接种价格的26.12%、20.68%时,ICUR<0。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the cost-effectiveness of administering two doses of different types of human papillomavirus (HPV) vaccines to 12-year-old female adolescents. Methods: A decision tree Markov model with genital warts and cervical cancer as target diseases was established to analyze the effects, costs, and Quality Adjusted Life Years (QALY) of strategies such as no vaccination, two doses of bivalent HPV (HPV-2), two doses of quadrivalent HPV (HPV-4), and two doses of nine-valent HPV (HPV-9) in a 12-year-old female adolescent cohort in 2023 using 50% of the procurement price or self-funded vaccination price in pilot provinces. The number of avoided cases of cervical cancer and genital warts and the incremental cost-utility ratio (ICUR) were compared between different strategies. Results: Compared with non-vaccination, female adolescents who received two doses of HPV-2, HPV-4 and HPV-9 were able to avoid 55.2% of cervical cancer cases with HPV-2, 77.11% and 78.68% of genital warts with HPV-4, and 54.99% and 73.46% of cervical cancer with HPV-9, respectively. The ICUR of strategies HPV-2, HPV-4, and HPV-9 was -28 470.44 yuan/QALY, 29 328.26 yuan/QALY and 48 106.85 yuan/QALY, respectively. HPV-2 was the most economical strategy and could achieve net cost savings. Single-factor sensitivity analysis showed that the results were robust, and the most influential factors were discount rate, vaccine prices and direct medical costs for low-grade precancerous lesions. The probability sensitivity analysis showed that compared with the national gross domestic product (GDP) per capita in 2023, the probability of cost-utility of HPV-2, HPV-4 and HPV-9 compared with non-vaccination was 99.51%, 89.03% and 67.81%, respectively. Only when the price of a single dose of HPV-4 and HPV-9 vaccines was lower than 26.12% and 20.68% of the current self-funded vaccination price, respectively, could there be a net cost saving. Conclusion: In the case where HPV-2 adopts the pilot province procurement price and the multivalent vaccine adopts a 50% self-funded vaccination price, the vaccination of 12-year-old female adolescents with HPV-2, HPV-4 and HPV-9 has cost-effectiveness, and HPV-2 is the most economical strategy. 目的: 分析12岁女性青少年接种2剂不同类型的人乳头瘤病毒(HPV)疫苗的成本效用。 方法: 建立决策树-马尔科夫模型,以生殖器疣和宫颈癌为目标疾病,采用试点省份招采价格或自费接种疫苗价格的50%进行分析,模拟2023年12岁女性青少年队列,估算不接种、接种2剂二价(HPV-2)、2剂四价HPV(HPV-4)、2剂九价HPV(HPV-9)策略下效果、成本和质量调整生命年(QALY),比较不同策略之间避免的宫颈癌和生殖器疣病例数以及增量成本效用比(ICUR)。 结果: 12岁女性青少年接种2剂HPV-2、HPV-4、HPV-9与不接种相比,HPV-2可以避免55.2%的宫颈癌发生,HPV-4和HPV-9分别可以避免77.11%、78.68%的生殖器疣和54.99%、73.46%的宫颈癌发生;策略HPV-2、HPV-4、HPV-9的ICUR分别为-28 470.44 元/QALY、29 328.26 元/QALY、48 106.85 元/QALY。单因素敏感性分析显示,影响较大的因素为贴现率、疫苗价格、低级别癌前病变直接医疗成本等因素。概率敏感性分析显示,与2023年全国人均国内生产总值比较,与不接种相比HPV-2、HPV-4、HPV-9具有成本效用的概率分别为99.51%、89.03%、67.81%;单剂HPV-4、HPV-9疫苗价格分别低于当前自费接种价格的26.12%、20.68%时,ICUR<0。 结论: 在HPV-2采用试点省份招采价格,多价疫苗采用50%自费接种价格的情况下,12岁女性青少年接种 HPV-2、HPV-4、HPV-9均具有成本效用,HPV-2是最具经济性的策略。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li JH, Liu XX, Tang L, et al. [Health economics evaluation of vaccination strategies for different human papillomavirus vaccines for 12-year-old female adolescents in China]. Zhonghua Yu Fang Yi Xue Za Zhi. 2025. PMID: 40176663. doi:10.3760/cma.j.cn112150-20241120-00925

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。